Go Deep
Sudeep Pharma Limited
Sudeep Pharma Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 19,368 | 64.7 | 13.49 | 0.17 | 1,055.00 |
| Oct 2026 | 18,526 | 62.4 | 13.02 | 0.17 | 1,018.40 |
Sudeep Pharma Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 1,582,705,000.0 | 1,823,387,000.0 | 1,723,356,000.0 | 1,626,662,000.0 |
| Net Profit | 405,500,000.0 | 488,766,000.0 | 474,617,000.0 | 457,472,000.0 |
| EPS | 3.6 | — | 4.3 | 4.1 |
Sudeep Pharma Limited Revenue & Profit: Last 4 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 6,388,014,000.0 | 4,974,078,000.0 | 4,546,660,000.0 | 4,261,710,000.0 |
| Net Profit | 1,728,926,000.0 | 1,387,292,000.0 | 1,331,870,000.0 | 623,210,000.0 |
| EPS | 15.5 | 12.3 | 11.8 | 5.5 |
Sudeep Pharma Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Total Assets | 11,748,765,000.0 | 7,171,708,000.0 | 5,138,660,000.0 | 4,201,130,000.0 |
| Total Liabilities | 2,767,847,000.0 | 2,240,784,000.0 | 1,578,320,000.0 | 1,968,280,000.0 |
| Total Equity | 8,833,380,000.0 | 4,930,924,000.0 | 3,560,340,000.0 | 2,232,850,000.0 |
Owes vs Owns
Sudeep Pharma Limited owed ₹0.24 for every ₹1 it owned in Mar 2026, down from ₹0.47 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.24× | 0.31× | 0.31× | 0.47× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Sudeep Pharma Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 9.8%Receivables 19.4%Inventory 18.4%Fixed assets (tangible) 38.5%Intangible assets 6.4%Long-term investments 1.3%Other assets 6.3%
How it's funded — Mar 2026
Short-term debt 9.7%Long-term debt 2.9%Payables 5.8%Other liabilities 5.1%Shareholders' equity 76.4%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 114.6 | 51.9 | 14.1 | 13.3 |
| Receivables | 227.5 | 185.4 | 144.6 | 93.7 |
| Inventory | 216.0 | 128.7 | 66.6 | 71.0 |
| Fixed assets (tangible) | 452.4 | 286.3 | 232.5 | 186.9 |
| Intangible assets | 75.0 | 0.2 | 0.3 | 0.4 |
| Long-term investments | 15.0 | 0.1 | 0.3 | 0.2 |
| Other assets | 74.2 | 64.6 | 55.5 | 54.6 |
| Liabilities & equity | ||||
| Short-term debt | 114.0 | 95.7 | 63.9 | 62.3 |
| Long-term debt | 34.3 | 39.6 | 11.1 | 19.9 |
| Payables | 68.4 | 60.5 | 50.7 | 38.5 |
| Other liabilities | 60.1 | 28.3 | 32.1 | 76.1 |
| Shareholders' equity | 898.1 | 493.1 | 356.0 | 223.3 |
| Net tangible assets | 808.3 | 492.9 | 355.7 | 222.9 |
Sudeep Pharma Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Operating Activities | 695,530,000.0 | 487,267,000.0 | 656,850,000.0 | 483,950,000.0 |
| Investing Activities | -3,309,298,000.0 | -787,556,000.0 | -492,810,000.0 | -500,160,000.0 |
| Financing Activities | 2,472,875,000.0 | 526,961,000.0 | -127,350,000.0 | -97,770,000.0 |